Drug Information

Drug General Information
Drug ID
D0H1AY
Former ID
DIB008884
Drug Name
AQW-051
Drug Type
Small molecular drug
Indication Alzheimer disease [ICD9: 331; ICD10:G30] Phase 2 [523693], [542393]
Company
Novartis AG
Structure
Download
2D MOL
Formula
C19H22N2O
InChI
InChI=1S/C19H22N2O/c1-14-2-4-15(5-3-14)18-7-6-17(12-20-18)22-19-13-21-10-8-16(19)9-11-21/h2-7,12,16,19H,8-11,13H2,1H3/t19-/m0/s1
InChIKey
NPDLTEZXGWRMLQ-IBGZPJMESA-N
PubChem Compound ID
50914822
PubChem Substance ID
113031102, 121162489, 140787356, 141925444, 173020003, 178103943, 224035100, 227667656, 245638410
Target and Pathway
Target(s) Neuronal acetylcholine receptor protein, alpha-7 chain Target Info Agonist [532935]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Cholinergic synapse
Nicotine addiction
Chemical carcinogenesis
PANTHER Pathway Alzheimer disease-amyloid secretase pathway
Nicotinic acetylcholine receptor signaling pathway
Reactome Highly calcium permeable postsynaptic nicotinic acetylcholine receptors
WikiPathways SIDS Susceptibility Pathways
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
References
Ref 523693ClinicalTrials.gov (NCT01474421) Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease. U.S. National Institutes of Health.
Ref 542393(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7371).
Ref 532935AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord. 2014 Nov;20(11):1119-23.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.